Skip to main content Accessibility help
×
Home
Hostname: page-component-78dcdb465f-2ktwh Total loading time: 0.338 Render date: 2021-04-17T15:38:38.206Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": false, "newCiteModal": false, "newCitedByModal": true }

Jordan W. Smoller, MD, ScD

Published online by Cambridge University Press:  07 November 2014

Abstract

Although most patients with depression ultimately respond to antidepressant therapy, >50% have inadequate response to an individual antidepressant trial. The desire to avoid adverse drug reactions is common among patients, and is an important determinant of drug selection among psychiatrists. However, since the major classes of antidepressants and antipsychotics appear to be comparable in efficacy, clinicians have little basis for selecting the most effective agent for an individual patient. Pharmacogenetics, often described as the study of genetic variation that explains differential response to medication, represents an important new avenue toward improving treatment outcomes. Genetic variation in drug-metabolizing enzymes has been recognized for decades. The main focus of current psychiatric pharmacogenetic testing is on the cytochrome P450 (CYP) 2D6 and, to a somewhat lesser extent, on the 2C19 genes. Data suggest that poor metabolizer status can be associated with an increased risk of adverse drug reactions with certain medications, and that ultra-rapid metabolizers may require higher-than-usual doses to achieve a therapeutic response. The importance of CYP enzymes in the metabolism of several antidepressant and antipsychotic drugs suggest that genetic variation may aid in medication selection or dosing. Advances in pharmacogenetic research may facilitate the development of personalized medicine in which genetic information can inform drug selection, leading to optimal drug effectiveness and minimal drug toxicity.

In this monograph, David A. Mrazek, MD, provides an overview of the context of genetic testing in clinical psychiatric practice. Next, Jordan W. Smoller, MD, ScD, discusses some of the practical issues related to medication selection. Finally, Jose de Leon, MD, presents a comprehensive review of antidepressant and antipsychotic treatment based on drug metabolism, and reviews the available testing methods for CYP 2D6 and 2C19 genotypes.

Type
Research Article
Copyright
Copyright © Cambridge University Press 2003

Access options

Get access to the full version of this content by using one of the access options below.

References

1.Trivedi, MH, Rush, AJ, Wisniewski, SR, et al.Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:2840.CrossRefGoogle ScholarPubMed
2.Whooley, MA, Simon, GE. Managing depression in medical outpatients. N Engl J Med. 2000;343:19421950.CrossRefGoogle ScholarPubMed
3.Malhotra, AK, Murphy, GM Jr., Kennedy, JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry. 2004;161:780796.CrossRefGoogle ScholarPubMed
4.Phillips, KA, Van Bebber, SL. Measuring the value of pharmacogenomics. Nat Rev Drug Discov. 2005;4:500509.CrossRefGoogle ScholarPubMed
5.Kirchheiner, J, Nickchen, K, Bauer, M, et al.Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry. 2004;9:442473.CrossRefGoogle ScholarPubMed
6.Desta, Z, Zhao, X, Shin, JG, Flockhart, DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41:913958.CrossRefGoogle ScholarPubMed
7.Ingelman-Sundberg, M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci. 2004;25:193200.CrossRefGoogle ScholarPubMed
8.Brockmoller, J, Kirchheiner, J, Schmider, J, et al.The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther. 2002;72:438452.CrossRefGoogle ScholarPubMed
9.Sindrup, SH, Brosen, K, Gram, LF, et al.The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther. 1992;51:278287.CrossRefGoogle ScholarPubMed
10.Spina, E, Gitto, C, Avenoso, A, Campo, GM, Caputi, AP, Perucca, E. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur J Clin Pharmacol. 1997;51:395398.CrossRefGoogle ScholarPubMed
11.Bertilsson, L, Mellstrom, B, Sjokvist, F, Martenson, B, Asberg, M. Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet. 1981;1:560561.CrossRefGoogle ScholarPubMed
12.Lessard, E, Yessine, MA, Hamelin, BA, O'Hara, G, LeBlanc, J, Turgeon, J. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics. 1999;9:435443.Google ScholarPubMed
13.Roberts, RL, Mulder, RT, Joyce, PR, Luty, SE, Kennedy, MA. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Hum Psychopharmacol. 2004;19:1723.CrossRefGoogle ScholarPubMed
14.Murphy, GM Jr., Kremer, C, Rodrigues, HE, Schatzberg, AF. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry. 2003;160:18301835.CrossRefGoogle ScholarPubMed
15.Murphy, GM Jr., Hollander, SB, Rodrigues, HE, Kremer, C, Schatzberg, AF. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry. 2004;61:11631169.CrossRefGoogle ScholarPubMed
16.Wilkinson, GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005;352:22112221.CrossRefGoogle ScholarPubMed
17.Scordo, MG, Spina, E. Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics. 2002;3:201218.CrossRefGoogle ScholarPubMed
18.de Leon, J, Susce, MT, Pan, RM, Fairchild, M, Koch, WH, Wedlund, PJ. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry. 2005;66:1527.CrossRefGoogle ScholarPubMed
19.Vandel, P, Haffen, E, Vandel, S, et al.Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes. Eur J Clin Pharmacol. 1999;55:659665.CrossRefGoogle ScholarPubMed
20.Schillevoort, I, de Boer, A, van der Weide, J, et al.Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study. Pharmacogenetics. 2002;12:235240.CrossRefGoogle ScholarPubMed
21.Bertilsson, L, Dahl, ML, Dalen, P, Al-Shurbaji, A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol. 2002;53:111122.CrossRefGoogle ScholarPubMed
22.Kapitany, T, Meszaros, K, Lenzinger, E, et al.Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr Res. 1998;32:101106.CrossRefGoogle Scholar
23.Ohmori, O, Kojima, H, Shinkai, T, Terao, T, Suzuki, T, Abe, K. Genetic association analysis between CYP2D6*2 allele and tardive dyskinesia in schizophrenic patients. Psychiatry Res. 1999;87:239244.CrossRefGoogle ScholarPubMed
24.Tiwari, AK, Deshpande, SN, Rao, AR, et al.Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms. Schizophr Res. 2005;75:2126.CrossRefGoogle ScholarPubMed
25.de Leon, J, Susce, MT, Pan, RM, Koch, WH, Wedlund, PJ. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J Clin Psychopharmacol. 2005;25:448456.CrossRefGoogle ScholarPubMed
26.Arthur, H, Dahl, ML, Siwers, B, Sjoqvist, F. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J Clin Psychopharmacol. 1995;15:211216.CrossRefGoogle ScholarPubMed
27.Andreassen, OA, MacEwan, T, Gulbrandsen, AK, McCreadie, RG, Steen, VM. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacology (Berl). 1997;131:174179.CrossRefGoogle ScholarPubMed
28.Smits, KM, Smits, LJ, Schouten, JS, Stelma, FF, Nelemans, P, Prins, MH. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol Psychiatry. 2004;9:433441.CrossRefGoogle ScholarPubMed
29.Kawanishi, C, Lundgren, S, Agren, H, Bertilsson, L. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol. 2004;59:803807.Google ScholarPubMed
30.Kirchheiner, J, Brosen, K, Dahl, ML, et al.CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand. 2001;104:173–92.CrossRefGoogle ScholarPubMed
31.Zimmerman, M, Posternak, M, Friedman, M, et al.Which factors influence psychiatrists' selection of antidepressants? Am J Psychiatry. 2004;161:12851289.CrossRefGoogle ScholarPubMed
32.Baumann, P, Hiemke, C, Ulrich, S, et al.The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37:243265.CrossRefGoogle Scholar
33.Kirchheiner, J, Fuhr, U, Brockmoller, J. Pharmacogenetics-based therapeutic recommendations--ready for clinical practice? Nat Rev Drug Discov. 2005;4:639647.CrossRefGoogle ScholarPubMed
34.Perlis, RH, Mischoulon, D, Smoller, JW, et al.Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry. 2003;54:879883.CrossRefGoogle ScholarPubMed

Full text views

Full text views reflects PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.

Total number of HTML views: 0
Total number of PDF views: 13 *
View data table for this chart

* Views captured on Cambridge Core between September 2016 - 17th April 2021. This data will be updated every 24 hours.

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Jordan W. Smoller, MD, ScD
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Jordan W. Smoller, MD, ScD
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Jordan W. Smoller, MD, ScD
Available formats
×
×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *